Recon Strategy – Insights Blog

An Opinionated Take on NEJM Highlights for Q1 of 2026

The first quarter of 2026 NEJM featured several disruptive studies, including a Canadian‑Australian dialysis trial where fish‑oil supplementation halved myocardial infarctions and cut strokes by two‑thirds. Merck’s oral PCSK9 inhibitor enlicitide achieved a 57% LDL reduction, positioning it for a 2026‑27 FDA filing with a national priority voucher. PMV’s rezatapopt reactivated mutant TP53, delivering a 22% response rate in heavily pre‑treated solid tumors, while Avidity’s antibody‑oligo conjugate successfully delivered siRNA to muscle in myotonic dystrophy patients. Regeneron’s split‑AAV gene therapy restored hearing in most children with otoferlin‑related deafness, highlighting a new frontier for genetic medicine.